Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.48 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.48 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.48 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.48 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.48 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.48 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.48 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.43 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.43 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496589 | 0.98 | KDM4E (0.62) | KDM4ECYP3A4TSHRALDH1A1MAPK1 | |
| SCHEMBL30251861 | 0.98 | KDM4E (0.62) | KDM4ECYP3A4TSHRALDH1A1MAPK1 | |
| SCHEMBL27677437 | 0.88 | CYP3A4 (0.54) | KDM4ECYP3A4TSHRALDH1A1MAPK1 | |
| SCHEMBL7299469 | 0.86 | KDM4E (0.54) | KDM4ECYP3A4TSHRALDH1A1MAPK1 | |
| SCHEMBL7297926 | 0.84 | KDM4E (0.62) | KDM4ECYP3A4TSHRALDH1A1MAPK1 | |
| SCHEMBL30467838 | 0.84 | KDM4E (0.62) | KDM4ECYP3A4TSHRALDH1A1MAPK1 | |
| SCHEMBL260569 | 0.82 | KDM4E (0.60) | KDM4ECYP3A4TSHRALDH1A1MAPK1 | |
| SCHEMBL992781 | 0.82 | KDM4E (0.60) | KDM4ECYP3A4TSHRALDH1A1MAPK1 | |
| SCHEMBL29789796 | 0.82 | KDM4E (0.60) | KDM4ECYP3A4TSHRALDH1A1MAPK1 | |
| SCHEMBL31632586 | 0.82 | KDM4E (0.60) | KDM4ECYP3A4TSHRALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164848-B1 | POLYMORPHIC FORM OF GRANISETRON BASE, METHODS FOR OBTAINING IT AND FORMULATION CONTAINING IT | INKE SA (ES) | 2016-02-24 | — | — | EP | disclosed |
| US-8304426-B2 | Polymorphic form of Granisetron base, methods for obtaining it and formulation containing it | INKE, S.A. (ES) | 2012-11-06 | — | — | US | disclosed |
| EP-1484321-B1 | Process for preparing 1-methylindazole-3-carboxylic acid | CHEMAGIS LTD (IL) | 2011-04-06 | — | — | EP | disclosed |
| US-20100204264-A1 | POLYMORPHIC FORM OF GRANISETRON BASE, METHODS FOR OBTAINING IT AND FORMULATION CONTAINING IT | INKE, S.A. (ES) | 2010-08-12 | — | — | US | disclosed |
| WO-2007088557-A1 | PROCESS FOR HIGHLY PURE CRYSTALLINE GRANISETRON BASE | NATCO PHARMA LIMITED (IN) | 2007-08-09 | — | — | WO | disclosed |
| US-7071209-B2 | Process for preparing a pharmaceutically active compound (granisetron) | LABORATORIOS VITA, S.A. (ES) | 2006-07-04 | — | — | US | disclosed |
| US-7060841-B2 | Process for preparing 1-methylindazole-3-carboxylic acid | CHEMAGIS LTD. (IL) | 2006-06-13 | — | — | US | disclosed |
| EP-1487833-B1 | PROCESS FOR PREPARING A PHARMACEUTICALLY ACTIVE COMPOUND (GRANISETRON) | VITA CIENTIFICA S L (ES) | 2005-07-06 | — | — | EP | disclosed |
| US-20050124650-A1 | Process for preparing a pharmaceutically active compound (granisetron) | INKE, S.A. (ES) | 2005-06-09 | — | — | US | disclosed |
| US-20040248960-A1 | Process for preparing 1-methylindazole-3-carboxylic acid | CHEMAGIS LTD. (IL) | 2004-12-09 | — | — | US | disclosed |
| EP-0499995-B1 | Piperidine derivatives | NISSHIN FLOUR MILLING CO (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-5552398-A | TREATMENT OF IRRITABLE BOWEL DIARRHEA | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-09-03 | — | — | US | disclosed |
| US-5256656-A | Antiserotonine agent | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1993-10-26 | — | — | US | disclosed |
| EP-0223385-B1 | 8-Azabicyclo[3,2,1]octane and 9-azabicyclo[3,3,1]nonane derivatives | BEECHAM GROUP PLC (GB) | 1993-03-10 | — | — | EP | disclosed |
| US-5187166-A | Also useful as antipsychotic agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1993-02-16 | — | — | US | disclosed |
| EP-0499995-A2 | Piperidine derivatives | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1992-08-26 | — | — | EP | disclosed |
| EP-0469449-A1 | Azabicyclo derivatives | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1992-02-05 | — | — | EP | disclosed |
| US-5034398-A | Analgesics | BEECHAM GROUP P.L.C. (GB) | 1991-07-23 | — | — | US | disclosed |
| US-4886808-A | Indazolyl carboxylic acid amides useful for treating migraine clusters headache, trigeminal neuralgia or emesis | BEECHAM GROUP P.L.C. (GB) | 1989-12-12 | — | — | US | disclosed |
| EP-0223385-A2 | 8-Azabicyclo[3,2,1]octane and 9-azabicyclo[3,3,1]nonane derivatives | BEECHAM GROUP PLC (GB) | 1987-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204264-A1 | POLYMORPHIC FORM OF GRANISETRON BASE, METHODS FOR OBTAINING IT AND FORMULATION CONTAINING IT | HTR1A, AMY1A, AVPR2 | HTR3A 5/4885HTR3E 35/4885HTR3B 63/4885 |
| US-20040248960-A1 | Process for preparing 1-methylindazole-3-carboxylic acid | CYP3A43, CMA1, CYP3A7 | HTR3A 51/4885HTR3E 318/4885HTR3B 237/4885 |
| US-20050124650-A1 | Process for preparing a pharmaceutically active compound (granisetron) | TET2, TET1, CYP11B2 | HTR3A 1012/4885HTR3E 2144/4885HTR3B 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.